Search

Your search for "anpc" returned the following results.
Filter Results:
InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC), New Investor Group Sign $3.67M Equity Investment Agreements

September 27, 2022

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, has entered into legally binding investment agreements with nine institutional and individual investors; the agreements outline an investment in the company of approximately $3.67 million. According to the announcement, the various shares purchase […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces NASDAQ Delisting Appeal, Hearing

September 19, 2022

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, has filed a request with the NASDAQ Hearings Panel to appeal its delisting. The appeal, which was filed on Sept. 16, 2022, requests a hearing so that the company can present its […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Names New Board Members, Co-CEO

August 8, 2022

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company focused on early cancer screening and detection with operations in the United States and China, has appointed a new board member as well as a new board chair and co-CEO. ANPC board of directors announced that Jiawen Kang will be serving as a member of the board […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Releases Announcement Regarding Changes in Directors, Officers and Committees

July 19, 2022

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company focused on early cancer screening and detection with operations in the United States and China, has announced changes in the company’s directors and officers. The announcement stated that, on July 14, 2022, the company’s member approved written resolutions of a majority of the members. The resolutions addressed […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Regains Compliance to Remain Listed on Nasdaq Capital Market

June 10, 2022

AnPac Bio (NASDAQ: ANPC), a biotechnology company focused on early cancer screening and detection, today announced that The Nasdaq Stock Market LLC has determined that it has regained compliance with the requirements to remain listed on The Nasdaq Capital Market, as required by a hearing panel’s decision dated May 4, 2022, subject to a one-year […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Releases Financial Report for FY 2021

June 1, 2022

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company focused on early cancer screening and detection with operations in the United States and China, is reporting its financial results for the first quarter of fiscal year 2022, or the period ended March 31, 2022. The numbers are unaudited and have not yet been reviewed by the […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Releases Financial Report for FY 2021

May 17, 2022

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company focused on early cancer screening and detection with operations in the United States and China, is reporting its annual financial results for the year ended December 31, 2021. Highlights of the report include total revenues of $2.8 million, down 12.3% from $3.1 million in fiscal year 2020, along with […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Regains Compliance with MVPHS Requirement

May 11, 2022

AnPac Bio (NASDAQ: ANPC) is a biotechnology company with operations in the United States and China focused on early cancer screening and detection. The company today announced its receipt of notification from the Nasdaq Stock Market LLC that ANPC’s American Depositary Shares are now in compliance with the maintenance of the minimum market value of […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Receives Nasdaq Approval to Transfer Markets

May 6, 2022

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company focused on early cancer screening and detection with operations in the United States and China, announced that its request to transfer its American Depositary Shares from the Nasdaq Global Market to the Nasdaq Capital Market has been approved. The company anticipates continuing to list on the Nasdaq […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces New Appointments, Enters New Investment Agreement

April 11, 2022

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company focused on early cancer screening and detection with operations in the United States and China, has named a new CEO. Dr. Ai-dong Chen will be taking over the helm, replacing Dr. Chris Yu, AnPac founder, who resigned as board director, CEO and board chair. Chen was also […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Subsidiary Appraised, Approved to Explore Strategic Alternatives

March 3, 2022

AnPac Bio-Medical Science (NASDAQ: ANPC) subsidiary Changwei System Technology (Shanghai) Co. Ltd. has been evaluated and appraised by China Alliance Appraisal (Shanghai) Co. Ltd. One of the top 10 appraisers in China by revenue, China Alliance is certified and licensed by the China Appraisal Society under the Ministry of Finance. Fully owned by AnPac Bio, […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Files for Breakthrough Medical Device Designation with FDA

February 3, 2022

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company focused on early cancer screening and detection with operations in the United States and China, has filed for a breakthrough device designation request for its cancer differentiation analysis (“CDA”) technology-based medical device; the company filed the request with the Food and Drug Administration (“FDA”) earlier this week. […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Ranked No. 1 Globally in Multi-Cancer Screening and Detection Test Volume

January 25, 2022

AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in the United States and China, today announced that Frost & Sullivan Company, a leading and well-known U.S. market analysis and research firm, has ranked AnPac Bio globally as number one in worldwide multiple cancer screening and detection volume in a recent research report. Based on […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces Proprietary Medical Device Passes Registration Tests, Slated to Start Clinical Trial

January 4, 2022

AnPac Bio-Medical Science (NASDAQ: ANPC), a U.S.- and China-based biotechnology company focused on early cancer screening and detection, announced that its Class III medical device for lung cancer auxiliary diagnosis has passed stringent and rigorous registration tests; the tests were conducted at a testing laboratory selected by China’s regulatory agent for medical products, the National […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces Publication of Technical Paper on Biophysics-Based CDA Cancer Detection Technology

December 10, 2021

AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, today announced that its joint technical paper on novel Cancer Differentiation Analysis (“CDA”) Technology for multi-cancer screening with multiple leading medical institutions was accepted and published online. The piece was published on Nov. 30 by the Expert Review of Molecular […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Releases Financial, Operations Report for Latest Period

November 29, 2021

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, has reported its unaudited financial results and business highlights for the nine months ended Sept. 30, 2021. Financial highlights include total revenue reaching an estimated  $2.1 million, which is a 55.3% over […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Uniquely Positioned in Cancer Screening, Detection Market

November 15, 2021

AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, is the company behind a proprietary novel technology for early cancer screening and detection — the Cancer Differentiation Analysis (“CDA”). Powered by a database containing over 200,000 samples and cases, AnPac Bio’s CDA technology can detect and carry multifaceted information, […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Issues Update on Underwritten Public Offering of American Depositary Shares

November 11, 2021

AnPac Bio (NASDAQ: ANPC) today issued a correction to its press release dated Nov. 9, 2021, regarding the pricing of its underwritten public offering of American Depositary Shares (“ADSs”). According to the update, the original release referenced the dollar size of the offering and the number of ADSs being sold to include the exercise of […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) to Begin Proposed Public Offering

November 10, 2021

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced that it is starting an underwritten public offering; the offering is comprised of ANPC’s American Depositary Shares and is subject to market and other conditions. The announcement noted that there is […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) to Participate in Q4 Virtual Investor Summit

November 8, 2021

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced its participation in the Q4 Virtual Investor Summit, slated for Nov. 16–17, 2021. According to the announcement, AnPac head of investor relations, Phil Case, will present at the two-day event; AnPac’s […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Leveraging CDA Technology for Critical Early Cancer Detection

October 29, 2021

AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, since 2015 has commercially proven out its concepts through the development and sale of its cancer detection technology, Cancer Differentiation Analysis (“CDA”) for early detection of pre-cancerous disease and cancer. “The company has published numerous reports of clinical study results […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd.’s (NASDAQ: ANPC) Unique Platform Offering Comprehensive Blood Test Data, New Approach to Disease Screening

October 22, 2021

AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, has developed the Cancer Differentiation Analysis (“CDA”) technology — a proprietary approach to detect cancerous and pre-cancerous diseases. “CDA uses the blood’s natural biophysical properties to identify cancerous environments before tumors even form. The CDA platform, in which technology is […]

News Articles

AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) Among Leading Biotech Companies Innovating the Field of Early Cancer Screening and Detection

October 12, 2021

Blood and genomic testing are becoming preferable means of early cancer screening and detectionLeaders innovating this niche of the medical industry include AnPac Bio, Grail, Thrive and GuardantAnPac Bio-Medical’s testing features a database of more than 200,000 commercial and research multi-cancer test samples (probably the largest multi-cancer test data base) that detect up to 26 […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Stands Distinct in World of Cancer Prevention, Treatment

October 11, 2021

AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, is a proven early thought leader and developer of multi-cancer (also called pan-cancer) ideas and technology. “AnPac Bio is one of the first companies in the world to produce major theories and methods of multi-level, multi-parameter and multi-cancer screening. The […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces Study Results Confirming Correlation Between CDA Score, Risk of Cancer

October 4, 2021

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, has reached a significant milestone and positive result in its general-population, cancer-risk assessment tests and subsequent follow-up study. At the end of September 2021, healthcare providers confirmed more than 2,000 cancer, precancer […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) First Half Revenue Numbers Up by 128.5%, Non-GAAP Loss Down by 18.3%

October 1, 2021

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, has released it unaudited financial results for the six months ended June 30, 2021. Highlights of the report include total revenues reaching an estimated  $1.4 million, an increase of 128.5% compared to the same period in 2020; gross profit margin […]

News Articles

AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) 10 Years in the Making: Innovation Leads to Multi (Pan)-Cancer Screening

September 28, 2021

After ten years, the concept of (multi)pan-cancer screening pioneered by AnPac Bio-Medical Science Co., Ltd. (AnPac Bio) has finally been accepted and the industry is shifting toward early screening technology that detects multiple cancers in blood at one time. In 2010, AnPac Bio proposed the theory of multi-cancer screening. At the time, the industry was […]

News Articles

AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Leading the Way in Early Cancer Detection Space

September 27, 2021

Up to 50% of cancer is preventable, while other types can be detected or treated early, often resulting in complete remission for patients AnPac Bio-Medical Science Co., Ltd. uses blood-based testing to detect many types of cancer (multi-cancer tests) and pre-cancer diseases, predicting its potential to occur in the future Company’s proprietary CDA technology is […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd.’s (NASDAQ: ANPC) CDA Technology Detects Risk of Over 25 Different Cancer Types

September 24, 2021

AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, is a recognized innovator and leader in the field of early cancer screening and detection. Its core product and proven revenue generator, the pioneering Cancer Differentiation Analysis (“CDA”) platform, offers novel capabilities by looking for signals to help it assess […]

News Articles

AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Receives College of American Pathologists Accreditation for U.S. Laboratory

September 22, 2021

AnPac Bio’s clinical laboratories are located in the U.S. and China, with a total of 142 patents issued as of March 2021 Cancer Differentiation Analysis (“CDA”) technology is AnPac Bio’s approach to early cancer detection and screening technology, with over 200,000 samples and cases to serve as a way of approaching cancer screening Company’s ownership […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Leveraging Partnerships to Save Patients’ Lives, Broaden Product Pipeline

September 14, 2021

AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, recently announced a cooperation agreement with Roche Pharmaceuticals China, a subsidiary of Roche Holdings AG, to explore novel medical solutions. Under the agreement, “both parties plan to utilize AnPac Bio’s Cancer Differentiation Analysis (‘CDA’) cancer detection technology and Roche’s FoundationOne […]

News Articles

AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Files for National Medical Products Administration Registration of Early-Warning Cancer Technology with a Record 11 Tumor Types Under Formal Medical Device Product Registration

September 13, 2021

AnPac Bio-Medical Science Co., Ltd. has developed its proprietary Cancer Differentiation Analysis (“CDA”) technology to detect biophysical signals as an alternative early disease indicator to blood-based biomarker testing for cancer The company has laboratories and R&D facilities in China equipped for CDA testing and cancer biochemical testing, as well as a CLIA/CAP accredited laboratory in […]

News Articles

AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) Symposium Highlights the Application of Biophysical Technology in Cancer Prevention and Treatment

September 8, 2021

AnPac Bio-Medical Science Co., Ltd. held its 2021 technical symposium, entitled “The Applications of Biophysical Technology in Cancer Prevention and Treatment” in Shanghai, China, on August 6, 2021 The symposium included attendees from various hospitals, universities, and Fortune 500 companies, including Thermo Fisher Scientific and AnPac Bio’s contract partner Roche Pharmaceuticals China A recent report […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces Ownership Increase in Subsidiary Holding

September 7, 2021

AnPac Bio-Medical Science (NASDAQ: ANPC) subsidiary AnPac Bio-Medical Science (Lishui) Co. Ltd. has increased its holding in AnPai (Shanghai) Healthcare Management Consultant Co. Ltd., one of its subsidiaries; the increase came after approval was granted by the company audit committee and board of directors. The company announced that in late August 2021 it finalized the […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd.’s (NASDAQ: ANPC) CLIA Laboratory Receives Accreditation from the College of American Pathologists

August 30, 2021

AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, today announced that its Philadelphia, Pennsylvania-based Clinical Laboratory Improvement Amendments (“CLIA”) certified laboratory has received accreditation from the College of American Pathologists (“CAP”). The U.S. federal government recognizes the CAP Laboratory Accreditation Program, initiated in the early 1960s, as being […]

News Articles

AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Names CEO of AnPac Bio U.S. to Drive Adoption of Early Cancer Detection Technology

August 26, 2021

Early cancer detection technology innovator AnPac Bio-Medical Science Co. Ltd. has been awarded 142 patents with 95 patents pending as part of its bid to revolutionize cancer screening protocols AnPac Bio’s proprietary technology screens for a variety of biophysical properties and analyzes the results to establish risk factors for tumor development before tumor cells begin […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Files for Registration Testing of Its Multicancer CDA Device

August 23, 2021

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, has filed with China’s National Medical Products Administration (“NMPA”) for registration testing of its class III, multicancer detection medical device; the device, which has been tested and evaluated extensively, features AnPac’s proprietary Cancer Differentiation Analysis Technology (“CDA”). The company […]

InvestorNewsBreaks

InvestorNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces Seasoned Professional as US CEO

August 17, 2021

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, has appointed life-sciences veteran and biomedical scientist Dr. Sunil Pandit as its new U.S. CEO; the appointment is effective as of Aug. 16, 2021. The company noted that Pandit will lead AnPac Bio’s U.S. research and development efforts, as […]

News Articles

AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces New Cooperative and Partnership Agreements, and further Strengthens Board of Directors

Cooperation and partnership discussions: AnPac Bio has reported major corporations in the medical industry include Roche Pharmaceuticals China and Advanced Life Therapeutics Co., Ltd AnPac Bio holds 40% minority equity in Advanced Life Therapeutics, performing contract R&D on integrated circuit-based components for cancer treatment medical devices AnPac Bio’s board now includes Mr. Chao Feng who […]

News Articles

AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Featured in Coverage of Investor Summit Group’s Q3 Virtual Event

August 12, 2021

AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) is a biotechnology company focused on early cancer screening and detection, with 142 issued patents as of March 31, 2021. With two certified clinical laboratories in China and one CLIA registered clinical laboratory in the United States, AnPac Bio performs a suite of cancer screening and detection tests, […]

No ResultsNo content matches your search/filter.

 

 

 

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).